GENE:LSE:LSE- (GBX)

ETF | Others |

Last Closing

USD 1510.2

Change

-8.10 (-0.53)%

Market Cap

USD 0.16B

Volume

64.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

-0.16 (-0.06%)

USD 292,109.69B
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

+0.91 (+1.35%)

USD 292,109.19B
0R1O:LSE Amazon.com Inc.

+4.75 (+2.43%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+1.19 (+0.96%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.18 (+1.30%)

USD 608.02B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.23 (+1.32%)

USD 608.02B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+20.50 (+1.02%)

USD 321.87B
0QZK:LSE Coca-Cola Co.

-0.15 (-0.23%)

USD 266.08B
0QZO:LSE 0QZO

-0.80 (-0.78%)

USD 258.54B

ETFs Containing GENE:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.37% 51% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.37% 50% F 55% F
Trailing 12 Months  
Capital Gain 13.97% 66% D+ 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.97% 65% D 65% D
Trailing 5 Years  
Capital Gain 50.67% 70% C- 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.67% 68% D+ 73% C
Average Annual (5 Year Horizon)  
Capital Gain 17.42% 86% B+ 84% B
Dividend Return 17.42% 86% B+ 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 192.51% 11% F 10% F
Risk Adjusted Return 9.05% 36% F 48% F
Market Capitalization 0.16B 52% F 38% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.